Sri Krishna

Has grant

Stadtman Investigator

National Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Studying phenotypic states of antitumor human T cells

Open Date: 2023-01-01

Close Date: 2024-01-01

Grant: Close

Identifying antitumor T cell receptors for cellular immunotherapy

Open Date: 2023-01-01

Close Date: 2024-01-01

Articles (7)

Year:

2026

Year:

2025

Background Tumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often rare and exhausted, and ex vivo expansion can further reduce their frequencies. This complicates the identification of neoantigen-reactive T-cell receptors (TCRs) and the development of TIL products with high reactivity for patient treatment. Methods We tested whether TILs could be in vitro stimulated against neoantigens to achieve selective expansion of neoantigen-reactive TILs. Given their prevalence, mutant p53 or RAS were studied as models of human neoantigens. An in vitro stimulation method, termed “NeoExpand”, was developed to provide neoantigen-specific stimulation to TILs. 25 consecutive patient TILs from tumors harboring p53 or RAS mutations were subjected to NeoExpand. Results We show that neoantigenic stimulation achieved selective expansion of neoantigen-reactive TILs and broadened the neoantigen-reactive CD4 + and CD8 + TIL clonal repertoire. This allowed the effective isolation of novel neoantigen-reactive TCRs. Out of the 25 consecutive TIL samples, neoantigenic stimulation enabled the identification of 16 unique reactivities and 42 TCRs, while conventional TIL expansion identified 9 reactivities and 14 TCRs. Single-cell transcriptome analysis revealed that neoantigenic stimulation increased neoantigen-reactive TILs with stem-like memory phenotypes expressing IL-7R, CD62L, and KLF2. Furthermore, neoantigenic stimulation improved the in vivo antitumor efficacy of TILs relative to the conventional OKT3-induced rapid TIL expansion in p53-mutated or KRAS-mutated xenograft mouse models. Conclusions Taken together, neoantigenic stimulation of TILs selectively expands neoantigen-reactive TILs by frequencies and by their clonal repertoire. NeoExpand led to improved phenotypes and functions of neoantigen-reactive TILs. Our data warrant its clinical evaluation. Trial registration number NCT00068003 , NCT01174121 , and NCT03412877 .

Year:

2024

Year:

2024

Adoptive cell transfer (ACT) using neoantigen reactive T lymphocytes can mediate cancer regression. Here, we developed methods to isolate unique, personalized, neoantigen reactive T cell receptors (TCRs) from tumor infiltrating lymphocytes (TIL) from patients with metastatic gastrointestinal cancers and incorporate the TCR α and β chains into gamma retroviral vectors. We transduced autologous peripheral blood lymphocytes (PBL) using γ-retroviruses and adoptively transferred those cells into patients after lymphodepleting chemotherapy. We treated 7 patients with metastatic, mismatch-repair proficient colorectal cancers who had progressive disease following multiple prior therapies, and three patients had objective clinical responses by RECIST criteria including regressions of metastases to the liver, lung, and lymph nodes. All patients received T cell populations containing ≥50% TCR transduced cells, and all T cell populations were polyfunctional in that they secreted IFNα, GM-CSF, IL-2, and Granzyme B specifically in response to mutant peptides compared to wild type counterparts. TCR transduced cells were detected in the peripheral blood of 5 patients, including the three responders, at levels ≥10% of CD3+ cells approximately one month post-ACT. In one patient with a partial response to therapy, ~20% of CD3+ PBL expressed transduced TCRs more than two years after treatment. These studies demonstrate that ACT with T cells genetically modified to express personalized neoantigen reactive TCRs is safe and can mediate tumor regression in patients with metastatic solid epithelial cancers.

Year:

2024

Year:

2023

Year:

2023

Collaborators (3)

James Yang

National Cancer Institute

UNITED STATES
View details

Jared Gartner

National Institutes of Health

UNITED STATES
View details

sivasish sindiri

National Cancer Institute

UNITED STATES
View details